Briggids is a dynamic, global organisation with extensive experience in systematic reviews, health technology assessments, therapeutic value propositions/market access, landscape mapping and medical ...

Eli Lilly has partnered with insitro to advance new treatments for metabolic diseases, including metabolic ...

Merck & Co’s – known as MSD outside the US and Canada – Keytruda (pembrolizumab) and Astellas/Pfizer’s Padcev (enfortumab vedotin) have been approved by the Medicines and Healthcare products ...

GSK’s Arexvy has been shown to protect older adults against respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD) over three full RSV seasons. Results from the phase 3 ...

You can now start working on your entries and don’t forget to get them to us by Thursday 14 November by midnight to qualify for our early bird pricing. Entry deadline is Thursday 21 November and a ...

Merck & Co – known as MSD outside the US and Canada – has entered into a licence and research collaboration agreement worth ...

The 2024 edition of PMLiVE’s T40 list of creative agencies working on advertising, branding, creative and design projects in ...

Johnson & Johnson (J&J) has announced results from a real-world study comparing its Erleada (apalutamide) to Pfizer and ...

Researchers from the Institute of Cancer Research (ICR) have highlighted the potential benefits of treating bladder cancer with personalised radiotherapy. More than 130,000 patients are treated on the ...

AbbVie has shared positive top-line results from a late-stage study of its investigational Parkinson’s disease (PD) drug in ...

Eli Lilly has announced that it is investing $4.5bn into a new US facility for advanced manufacturing and drug development.